PH12017550051A1 - A pharmaceutical composition for treating gastrointestinal diseases - Google Patents
A pharmaceutical composition for treating gastrointestinal diseasesInfo
- Publication number
- PH12017550051A1 PH12017550051A1 PH12017550051A PH12017550051A PH12017550051A1 PH 12017550051 A1 PH12017550051 A1 PH 12017550051A1 PH 12017550051 A PH12017550051 A PH 12017550051A PH 12017550051 A PH12017550051 A PH 12017550051A PH 12017550051 A1 PH12017550051 A1 PH 12017550051A1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical composition
- gastrointestinal diseases
- treating gastrointestinal
- sucralfate
- ranitidine
- Prior art date
Links
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960004645 bismuth subcitrate Drugs 0.000 abstract 3
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 abstract 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 3
- 229960000620 ranitidine Drugs 0.000 abstract 3
- 229960004291 sucralfate Drugs 0.000 abstract 3
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients and a preparation method thereof. According to the present invention, when a combination drug of ranitidine, sucralfate and bismuth subcitrate is prepared, it is possible to address a hygroscopicity problem of ranitidine and increase formulation stability and drug bioavailability by controlling particle sizes of sucralfate and bismuth subcitrate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150015339 | 2015-01-30 | ||
| KR1020150147513A KR101583452B1 (en) | 2015-01-30 | 2015-10-22 | A pharmaceutical composition for treating gastrointestinal diseases |
| PCT/KR2016/000935 WO2016122226A2 (en) | 2015-01-30 | 2016-01-28 | A pharmaceutical composition for treating gastrointestinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12017550051A1 true PH12017550051A1 (en) | 2018-01-29 |
Family
ID=55169799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12017550051A PH12017550051A1 (en) | 2015-01-30 | 2017-07-25 | A pharmaceutical composition for treating gastrointestinal diseases |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3250199A4 (en) |
| JP (1) | JP6419347B2 (en) |
| KR (2) | KR101583452B1 (en) |
| CN (1) | CN107205947B (en) |
| AR (1) | AR105413A1 (en) |
| CL (1) | CL2017001680A1 (en) |
| CO (1) | CO2017006222A2 (en) |
| EA (1) | EA032385B9 (en) |
| EC (1) | ECSP17038599A (en) |
| GE (1) | GEP20196941B (en) |
| MA (1) | MA41432A (en) |
| MX (1) | MX375765B (en) |
| MY (1) | MY195824A (en) |
| PE (1) | PE20171340A1 (en) |
| PH (1) | PH12017550051A1 (en) |
| SA (1) | SA517382016B1 (en) |
| TW (1) | TWI635859B (en) |
| UA (1) | UA116517C2 (en) |
| WO (1) | WO2016122226A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101988479B1 (en) | 2017-10-11 | 2019-09-24 | (주)휴럼 | Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient |
| WO2019199134A1 (en) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | Pharmaceutical composition comprising lenalidomide |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3874917T2 (en) * | 1987-03-09 | 1993-03-04 | Procter & Gamble | COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF STOMACH. |
| US4990610A (en) * | 1988-08-25 | 1991-02-05 | Applied Analytical Industries, Inc. | Method for preparing high potency sucralfate |
| EP0403048A3 (en) * | 1989-06-14 | 1991-01-30 | Warner-Lambert Company | Medicated compositions containing sucralfate and processes for their production |
| KR970006083B1 (en) * | 1992-01-22 | 1997-04-23 | 주식회사 대웅제약 | A pharmaceutical composition for treating gastrointestinal disorders |
| ATE213635T1 (en) * | 1994-04-26 | 2002-03-15 | Chugai Pharmaceutical Co Ltd | METHOD FOR PRODUCING MELT-GRANULATED SUCRALFATE PREPARATION |
| JPH0879097A (en) * | 1994-09-01 | 1996-03-22 | Matsushita Electric Ind Co Ltd | Portable radio |
| KR970006083A (en) | 1995-07-06 | 1997-02-19 | 한승준 | Installation structure of wire fixing device of automobile cowl |
| WO1999010000A1 (en) * | 1997-08-25 | 1999-03-04 | The Procter & Gamble Company | Combined preparations for treating upper gastrointestinal tract distress |
| AU4655199A (en) | 1999-06-21 | 2001-01-09 | Dae Woong Pharmaceutical Co., Ltd. | Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate |
| JP2006076956A (en) * | 2004-09-10 | 2006-03-23 | Taiyo Yakuhin Kogyo Kk | Compounding agent for treating/preventing gastritis |
| KR101617054B1 (en) * | 2008-07-01 | 2016-04-29 | 라이온 가부시키가이샤 | Solid preparation for internal application |
| KR20110105223A (en) * | 2010-03-18 | 2011-09-26 | 일양약품주식회사 | Oral pharmaceutical compositions for the prevention or treatment of gastrointestinal diseases containing ilaprazole and a mixture of sucralate and bismuth preparations |
| KR20140072673A (en) * | 2012-12-05 | 2014-06-13 | (주)한국파비스제약 | Oral tablet for treatment of gastrointestinal disease |
-
2015
- 2015-10-22 KR KR1020150147513A patent/KR101583452B1/en active Active
- 2015-12-31 KR KR1020150190850A patent/KR20160094268A/en not_active Withdrawn
-
2016
- 2016-01-27 TW TW105102582A patent/TWI635859B/en active
- 2016-01-27 MA MA041432A patent/MA41432A/en unknown
- 2016-01-28 CN CN201680007680.7A patent/CN107205947B/en active Active
- 2016-01-28 GE GEAP201614551A patent/GEP20196941B/en unknown
- 2016-01-28 UA UAA201707833A patent/UA116517C2/en unknown
- 2016-01-28 JP JP2017540683A patent/JP6419347B2/en active Active
- 2016-01-28 WO PCT/KR2016/000935 patent/WO2016122226A2/en not_active Ceased
- 2016-01-28 EA EA201791458A patent/EA032385B9/en not_active IP Right Cessation
- 2016-01-28 MY MYPI2017702737A patent/MY195824A/en unknown
- 2016-01-28 EP EP16743704.5A patent/EP3250199A4/en not_active Withdrawn
- 2016-01-28 PE PE2017001147A patent/PE20171340A1/en unknown
- 2016-01-28 MX MX2017007567A patent/MX375765B/en active IP Right Grant
- 2016-01-29 AR ARP160100272A patent/AR105413A1/en not_active Application Discontinuation
-
2017
- 2017-06-20 EC ECIEPI201738599A patent/ECSP17038599A/en unknown
- 2017-06-23 CO CONC2017/0006222A patent/CO2017006222A2/en unknown
- 2017-06-23 CL CL2017001680A patent/CL2017001680A1/en unknown
- 2017-07-25 PH PH12017550051A patent/PH12017550051A1/en unknown
- 2017-07-29 SA SA517382016A patent/SA517382016B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160094268A (en) | 2016-08-09 |
| MX2017007567A (en) | 2017-10-19 |
| JP6419347B2 (en) | 2018-11-07 |
| MA41432A (en) | 2017-12-05 |
| UA116517C2 (en) | 2018-03-26 |
| MX375765B (en) | 2025-03-07 |
| WO2016122226A2 (en) | 2016-08-04 |
| EA032385B1 (en) | 2019-05-31 |
| EA032385B9 (en) | 2019-07-31 |
| CN107205947A (en) | 2017-09-26 |
| GEP20196941B (en) | 2019-01-10 |
| KR101583452B9 (en) | 2022-05-02 |
| EP3250199A2 (en) | 2017-12-06 |
| EP3250199A4 (en) | 2018-08-08 |
| MY195824A (en) | 2023-02-22 |
| AR105413A1 (en) | 2017-10-04 |
| WO2016122226A3 (en) | 2016-09-15 |
| CN107205947B (en) | 2020-05-22 |
| TW201639559A (en) | 2016-11-16 |
| CL2017001680A1 (en) | 2018-01-12 |
| CO2017006222A2 (en) | 2017-09-20 |
| JP2018503672A (en) | 2018-02-08 |
| BR112017013857A2 (en) | 2018-02-27 |
| KR101583452B1 (en) | 2016-01-11 |
| TWI635859B (en) | 2018-09-21 |
| SA517382016B1 (en) | 2021-03-18 |
| EA201791458A1 (en) | 2017-11-30 |
| PE20171340A1 (en) | 2017-09-13 |
| ECSP17038599A (en) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11202106160WA (en) | Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient | |
| PH12020550341A1 (en) | Niraparib formulations | |
| WO2014147611A8 (en) | Quinolines derivatives as novel anticancer agents | |
| ZA201707096B (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| EP3176163A4 (en) | Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient | |
| EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
| IL261196A (en) | Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient | |
| EP3093023A4 (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| EP3279210A4 (en) | Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient | |
| EP3138834A4 (en) | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | |
| MX2016001422A (en) | Pharmaceutical compositions of fingolimod. | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| EP3909597A4 (en) | Pharmaceutical composition for preventing or treating cancer, containing oligopeptide as active ingredient | |
| EP3352750A4 (en) | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | |
| PH12017550051A1 (en) | A pharmaceutical composition for treating gastrointestinal diseases | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| PH12019500024A1 (en) | Pharmaceutical compositions | |
| PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| EP3795170A4 (en) | Pharmaceutical composition comprising ccn5 as active ingredient, for preventing or treating retinal diseases | |
| SG11201801423PA (en) | Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof | |
| HK1233927A1 (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
| HK40005616A (en) | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |